Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Thyrocare Q4 Results Review - Efforts To Improvise Volume Growth Are Materialising: ICICI Securities
New initiates are driving volume growth Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of post results earning conference call
Thyrocare Technologies Results Earnings Call for Q4FY24
Conference Call with Thyrocare Technologies Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript. Thyrocare Technologies Ltd - 539871 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) regulation, 2015 Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board of directors of the Company at their meeting held on May 14, 2024, approved the appointment of Mr. Anandh Sundar and Mr. Nishant Shah as additional director designated as Independent Director wef June 15, 2024 Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation
We are enclosing herewith a copy of the Investor presentation to be made to the investors at the earning conference call for Analysts and Investors to be held on May 14, 2024 on the audited financial results of the Company for the quarter and year ended March 31, 2024. Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Dividend Updates
The Board has recommended a final dividend for Rs.18/- per share for the financial year 2023-24 for approval at ensuing Annual General Meeting Thyrocare Technologies Ltd - 539871 - Financials Results For The Quarter And Year Ended 31 March 2024
Please find attached herewith Audited financial results for the Quarter and year ended 31 March 2024. Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of Board Meeting Held On 14 May 2024
we wish to inform you that the Board has at its meeting held today i.e. May 14, 2024, inter alia, considered and approved the audited financial results (standalone and consolidated) for the quarter and financial year ended on March 31, 2024. Pursuant to Regulation 33(3) of SEBI Listing Regulations, the standalone and consolidated audited financial results for the quarter and financial year ended on March 31, 2024, along with the Audit Reports on said financial results issued by the Statutory Auditors of the Company, are attached as Annexure - A. The Board has recommended a final Dividend of Rs. 18/- per equity share of face value of Rs. 10/- each for the financial year 2023-24, for approval at the ensuing Annual General Meeting.